Jan. 8, 2018—Under the terms of the licensing agreement, Lundbeck has exclusively licensed rights to compounds developed at Vanderbilt that act on a receptor in the brain that has been implicated in schizophrenia.
Aug. 7, 2017—Developed at Vanderbilt, VU319 is designed to precisely target a specific neuron receptor associated with cognitive function while avoiding potentially dangerous side effects.
Dec. 27, 2016—Vanderbilt University scientists have received notification from the U.S. Food and Drug Administration that testing in humans may proceed for an investigational new drug for Alzheimer's disease after more than 10 years of research by scientists at Vanderbilt University and Vanderbilt University Medical Center.
Sep. 15, 2016—Researchers at Vanderbilt University Medical Center have discovered a key mechanism that explains how compounds they’re developing can suppress schizophrenia-like symptoms without side effects in mice.
Aug. 15, 2016—Research in the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) aimed at developing innovative new treatments for schizophrenia just received a powerful assist from The William K. Warren Foundation.
Jul. 8, 2015—Applying mild electrical stimulation to an area of the brain associated with cognitive control helps people with schizophrenia to recognize errors and adjust their behavior to avoid them.
May. 7, 2015—Vanderbilt University researchers have uncovered a surprising finding that could lead to the development of new, more effective therapies for schizophrenia, which affects more than 2 million Americans.
Mar. 19, 2015—There is growing evidence that disorders such as autism and schizophrenia involve deficits in what is called “multi-sensory processing,” the ability of the brain to properly integrate information coming in through the eyes, ears and other senses.